Form 4 for CLDI Calidi Biotherapeutics, Inc.
Accepted 2025-08-25 00:00:00 ET · period of report 2025-08-25 · accession 0001641172-25-025447 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-08-25 | 2025-08-21 | CLDI | Poma Eric E | CEO, Dir | P - Purchase | $2.00 | +25.0K | 25.0K | New | +$50.0K |
| D | 2025-08-25 | 2025-08-21 | CLDI | Poma Eric E | CEO, Dir | P - Purchase | — | +25.0K | 25.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-21 | P | A | 25,000 | $2.00 | 25,000 | D | — | — | (F2) Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant. |
| 2 | Derivative | Warrant (right to buy) | 2025-08-21 | P | A | 25,000 | — | 25,000 | D | $2.00 · 2025-08-21 to 2030-08-21 | 25,000 Common stock | (F2) Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant. |